SynAct Pharma’s FY25 results reflect a year of solid execution, highlighted by the continued advancement of lead asset resomelagon in the Ph...
Redeye comments on SynAct Pharma's directed share issue of gross cSEK52m.
Redeye reviews SynAct Pharma's Q4 report. A new European study in respiratory insufficiency was initiated in February.
Redeye comments on the full recruitment of the phase IIb ADVANCE study in RA with 240 patients.
Redeye is optimistic about the new investigator-sponsored phase II trial in respiratory infections, seeing it as improving the investment ca...
SynAct Pharma is focused on inflammation resolution therapeutics.
Redeye reviews SynAct Pharma's Q3 report. The ADVANCE study is progressing and on track to enrol all patients before year-end 2025.
Redeye views Hunter Capital's purchase of shares and warrants from Heights Capital Management as opening the way for further share price inc...
Redeye comments on SynAct Biopharma’s Q2 report. After a directed share issue, loan agreement with Hunter Capital and HCM exercising warrant...
Redeye is optimistic about the second warrant conversion from HCM.
Redeye comments on the conversion of warrants and Cantargia's deal yesterday.
Redeye updates its base case of Synact following the directed share issue and new programme in polymyalgia rheumatica, which broadens resome...
Redeye is positive about SynAct’s new directed issue and loan agreement with Hunter Capital, both of which have attractive conditions for th...
Redeye comments on SynAct's Q1 report, which includes the initiation of a new phase II study in Dengue fever and new patents.
Redeye is optimistic about the start of a well-sized phase II study in patients with Dengue fever and provides an updated base case.
Redeye comments on Synact's Q4 report. Synact raised in total SEK65m from a combined rights and directed share issue in December-January.
Redeye comments on SynAct’s successful rights issue.
Redeye initiates coverage of SynAct Pharma, a biotech company advancing a novel approach to controlling inflammation through resolution rath...
